Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Imatinib considered cost-effective CML treatment in Brazil

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Mataveli F, Calabró A, Mendes W, Vianna D, Dorlhiac-Llacer P, Bigni R, Hungria V.Cost-effectiveness of imatinib versus interferon-alpha in the treatment of patients newly diagnosed with chronic myeloid leukemia, under the Brazilian Public Healthcare System perspective. Blood 108: 946, No. 11, Part 1, Nov 2006

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Imatinib considered cost-effective CML treatment in Brazil. Pharmacoecon. Outcomes News 520, 6 (2007). https://doi.org/10.2165/00151234-200705200-00016

    Download citation

    Keywords

    • Interferon
    • Imatinib
    • Cost Effectiveness
    • Chronic Myeloid Leukaemia
    • System Perspective